Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Terminated Phase 2 Interventional Results available

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

NCT02137252
View directory record Official record
Conditions
Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions
Naltrexone, Sugar Pill
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography

NCT01669148
View directory record Official record
Conditions
Breast Cancer
Interventions
Tomosynthesis, Conventional
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Not applicable Interventional Results available

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study

NCT06975085
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Presentation of a personal breast cancer risk estimate
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
39 Years to 74 Years · Female only
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Partnership for Healthy Seniors

NCT00379743
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Cancer, Prostate Cancer
Interventions
Health coordinator (or patient navigator), Educational materials only
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
65 Years and older
Enrollment
2,593 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Not applicable Interventional

Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer

NCT01014715
View directory record Official record
Conditions
Breast Cancer
Interventions
Phase II - Preoperative Radiation followed by Lumpectomy.
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Columbia, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 1 Interventional

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

NCT00388076
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Pazopanib, Lapatinib, paclitaxel, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Brunswick, New Jersey • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915
View directory record Official record
Conditions
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions
Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 29, 2026, 12:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Elacestrant in Advanced Triple Positive Breast Cancer

NCT07612215
View directory record Official record
Conditions
ER Positive, HER2 Positive Breast Cancer
Interventions
Elacestrant, Trastuzumab, Pertuzumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 2 Interventional Results available

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Testosterone Cream, Estring
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 29, 2026, 12:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Early Phase 1 Interventional

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

NCT00436410
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 29, 2026, 12:05 PM EDT
Withdrawn No phase listed Observational

Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples

NCT01792882
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Hematologic Cancer
Interventions
Not listed
Lead sponsor
Global BioClinical
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 29, 2026, 12:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

NCT02115282
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
652
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 12:05 PM EDT
Withdrawn Not applicable Interventional

Subzero and Scorpion Trial

NCT05032079
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
cryoablation
Procedure
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 95 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women

NCT00084344
View directory record Official record
Conditions
Breast Cancer
Interventions
4-hydroxytamoxifen, breast imaging study, radiomammography
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 29, 2026, 12:05 PM EDT
Withdrawn No phase listed Observational

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

NCT03161834
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Observational
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 1 Interventional

A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors

NCT03980509
View directory record Official record
Conditions
Breast Cancer
Interventions
Curcumin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

NCT01068704
View directory record Official record
Conditions
Breast Cancer
Interventions
BMS-690514, Lapatinib, Letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Abilene, Texas • Beaumont, Texas • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 29, 2026, 12:05 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

NCT00267449
View directory record Official record
Conditions
Breast Cancer
Interventions
SoftScan Optical Breast Imaging System
Device
Lead sponsor
ART Advanced Research Technologies Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
3
States / cities
La Jolla, California • Stanford, California • Stuart, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 29, 2026, 12:05 PM EDT
Terminated Not applicable Interventional

Development of Real-time Image-guided Radiotherapy

NCT03524248
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Skin Cancer
Interventions
Image guided radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Advanced Solid Tumors

NCT00030615
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Melanoma, Stage III Melanoma, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
decitabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 29, 2026, 12:05 PM EDT
Completed Phase 2 Interventional

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

NCT00003035
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 29, 2026, 12:05 PM EDT
Not yet recruiting Phase 1 Interventional

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

NCT07454668
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
Interventions
Trastuzumab Deruxtecan, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 12:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

NCT07146568
View directory record Official record
Conditions
Lung Cancer, Cancer of the Lung
Interventions
Pink and Pearl Campaign
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years and older
Enrollment
5,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 12:05 PM EDT